drugset / Trial / NCT00163215

Growth Retardation In Children With Special Pathological Conditions Or Disease

NCT00163215

Phase 3 Completed 46 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To show an increase in annual growth rate 3 years after Visit 2. Annual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of GH treatment.

Timeline

Start
2005-01
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.0033 mg/kg
Subject Somatropin Protein / enzyme biologic 0.0067 mg/kg